Company Overview
Company Type: Public Company
Website: imaginmedical.com
Number of Employees: -
Ticker: IME (CNSX)
Year Founded: 1986


Business Description
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It offers the i/Blue Imaging System, which detects bladder cancer with advanced proprietary optics and light sensors; and enCage Coil, a disposable and focal therapy precision ablation device for use in the treatment of prostate cancer. The company is also developing technologies to visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. It has a license agreement with Lawrence Livermore National Security, LLC to develop and commercialize the i/Blue Imaging System. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
1.0
EBITDA
(2.3)
Total Enterprise Value
11.9
TEV/EBITDA
NM
EBIT
(2.4)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(3.3)
Total Debt
11.0
Price/Tang BV
NM
Total Assets
1.1
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Hutchens, Edward James
CEO, President & Director
Vacha, John F.
CFO & Corporate Secretary
Vergano, Michael G.
Director of Operations

Key Board Members
Name
Title
Slawin, Kevin M.
Independent Chairman of the Board
Hutchens, Edward James
CEO, President & Director
Namvar, Kayvon 
Independent Director
Bianco, Fernando 
Medical Advisor of Prostate Cancer
Bivalacqua, Trinity J.
Medical Advisor of Bladder Cancer
Bleck, Christopher A.
Independent Director
Daignault, Kenneth 
Independent Director
Emberton, Mark 
Medical Advisor of Prostate Cancer
Kamat, Ashish M.
Medical Advisor of Bladder Cancer
Matulewicz, Richard 
Medical Advisor of Bladder Cancer
Orczyk, Clement 
Medical Advisor of Prostate Cancer
Taneja, Samir 
Medical Advisor of Prostate Cancer


Primary Industry Classification
Health Care Equipment


Primary Office Location
890 West Pender Street Suite 600 | Vancouver, BC | V6C 1L9 | Canada

Current and Pending Investors
Alumina Partners LLC, Rapha Capital Management, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.09
Market Cap (mm)
1.0
Open
 0.09
Shares Out. (mm)
10.8
Previous Close
 0.09
Float %
85.6%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(10.0)%
Dividend Yield %
-
Day High/Low
 0.09/ 0.09
Diluted EPS Excl. Extra Items
(0.31)
52 wk High/Low
 0.29/ 0.06
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0025
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
1.44


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
CNSX:IME - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Expedition Mining Inc.
As of February 9, 2016, Expedition Mining Inc. was acquired by Imagin Medical Inc., in a reverse merger transaction. Expedition Mining Inc., a resource exploration company, engages in the acquisition, exploration, and development of mineral properties in the United States and Canada. It primarily focuses on the Long Canyon gold property in Nevada. The company was formerly known as Universal Uranium Ltd. and changed its name to Expedition Mining Inc. in July 2010. Expedition Mining Inc. is headquartered in Vancouver, Canada.

United States and Canada
Gold
-
0.00
0.00
BSS Life Sciences Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-22-2022
-
Private Placement
Target
Imagin Medical Inc. (CNSX:IME)
Rapha Capital Management, LLC Buyer Funds:Rapha Capital BioVentures Fund I, LP

7.25
Feb-18-2021
-
Public Offering
Target
Imagin Medical Inc. (CNSX:IME)


-
Nov-10-2020
-
Public Offering
Target
Imagin Medical Inc. (CNSX:IME)


-
Oct-22-2020
Aug-26-2021
Private Placement
Target
Imagin Medical Inc. (CNSX:IME)


2.90
Jan-07-2020
Jan-21-2020
Private Placement
Target
Imagin Medical Inc. (CNSX:IME)


1.46
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-05-2023
Company Conference Presentations
Imagin Medical Inc. Presents at Emerging Growth Conference 53, Apr-05-2023 10:15 AM
Dec-22-2022
Annual General Meeting
Imagin Medical Inc., Annual General Meeting, Dec 22, 2022
Dec-22-2022
Auditor Going Concern Doubts
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt
Aug-22-2022
Private Placements
Imagin Medical Inc. announced that it expects to receive $7.25 million in funding from Rapha Capital Management, LLC and other investors
Dec-24-2021
Auditor Going Concern Doubts
Imagin Medical Inc. Auditor Raises 'Going Concern' Doubt


Advisors
Most Recent Auditor
DeVisser Gray LLP


Most Recent Auditor
De Visser Gray


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
MarketLine

Sep 20, 2023 06:01 AM
IME
Imagin Medical Inc
Reports
26
MarketLine

Aug 31, 2023 06:01 AM
IME
Imagin Medical Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
200
CFRA Equity Research

Jan 03, 2023 10:33 AM
IME
Imagin Medical Inc.
Reports
9
Timetric Limited
Timetric Research Team
May 22, 2018 05:53 AM
IME
Imagin Medical Inc. (EXU) - Company Capsule
Reports
23
GlobalData

Oct 26, 2016 04:06 AM
IME
Imagin Medical Raises USD0.3 Million in Private Placement of Units
Reports
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Rapha Capital Management, LLC

831,726

7.68

0.1

Apr-12-2023


Next Edge Capital Corp.

620,000

5.72

0.1

Jun-30-2023


Hutchens, Edward James

415,312

3.83

0.0

Nov-21-2022


Slawin M.D., Kevin M.

150,000

1.39

0.0

Feb-14-2023


Vacha CPA, John F.

129,503

1.20

0.0

Apr-22-2022


Bleck, Christopher A.

13,961

0.13

0.0

Nov-21-2022


Daignault, Kenneth 

13,899

0.13

0.0

Nov-21-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Next Edge Capital Corp.
620,000
38,500
Rapha Capital Management, LLC
831,726
17,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
enCage Coil, i/Blue Imaging System (Future), i/Red Imaging System (Future), i/Vision Imaging System (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Company Conference Presentations
Dec-22-2023
Estimated Earnings Release Date (S&P Global Derived)
Apr-28-2024
Company Conference Presentations
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-29-2023
Jun-30-2023
Imagin Medical Inc. (CNSX:IME)
SEDAR
Interim Financial Statements
558 KB
May-24-2023
Mar-31-2023
Imagin Medical Inc. (CNSX:IME)
SEDAR
Interim Financial Statements
567 KB
Feb-10-2023
Dec-31-2022
Imagin Medical Inc. (CNSX:IME)
SEDAR
Interim Financial Statements
559 KB
Dec-22-2022
Sep-30-2022
Imagin Medical Inc. (CNSX:IME)
SEDAR
Annual Financial Statements
79 KB
Dec-22-2022
Sep-30-2022
Imagin Medical Inc. (CNSX:IME)
SEDAR
Annual Financial Statements
67 KB
Dec-22-2022
Sep-30-2022
Imagin Medical Inc. (CNSX:IME)
SEDAR
Annual Financial Statements
266 KB
Nov-28-2022
-
Imagin Medical Inc. (CNSX:IME)
SEDAR
Management Proxy Materials
67 KB
Nov-28-2022
-
Imagin Medical Inc. (CNSX:IME)
SEDAR
Management Proxy Materials
28 KB
Nov-28-2022
-
Imagin Medical Inc. (CNSX:IME)
SEDAR
Management Proxy Materials
232 KB
Oct-27-2022
-
Imagin Medical Inc. (CNSX:IME)
SEDAR
Notice of the Meeting and Record Date
312 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Rapha Capital Management, LLC
Mar-20-2023 - Apr-12-2023
Common Shares
22,000
4,390
Open Market Acquisition
2.72
Multiple
-
Apr-12-2023
Common Shares
4,500
1,013
Open Market Acquisition
-
Exchange Announcement
-
Apr-06-2023
Common Shares
3,000
611
Open Market Acquisition
-
Exchange Announcement
-
Apr-03-2023
Common Shares
5,000
1,024
Open Market Acquisition
-
Exchange Announcement
-
Mar-30-2023
Common Shares
2,000
386
Open Market Acquisition
-
Exchange Announcement
-
Mar-20-2023
Common Shares
3,000
603
Open Market Acquisition
-
Exchange Announcement
-
Apr-12-2023
Common Shares
4,500
752
Open Market Acquisition
-
Exchange Announcement
Rapha Capital Management, LLC
Mar-02-2023
Common Shares
40,000
8,012
Open Market Acquisition
5.20
Multiple
Rapha Capital Management, LLC
Feb-28-2023
Common Shares
15,000
3,021
Open Market Acquisition
1.99
Multiple
Rapha Capital Management, LLC
Feb-23-2023
Common Shares
5,000
1,015
Open Market Acquisition
0.67
Multiple
Rapha Capital Management, LLC
Feb-14-2023
Common Shares
21,000
4,324
Open Market Acquisition
2.88
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Slawin, Kevin M.
Independent Chairman of the Board
-
-

Hutchens, Edward James
CEO, President & Director
(833) 246-2446
(508) 651-8955
jhutchens@imaginmedical.com
Namvar, Kayvon 
Independent Director
-
-

Bianco, Fernando 
Medical Advisor of Prostate Cancer
-
-

Bivalacqua, Trinity J.
Medical Advisor of Bladder Cancer
-
-

Bleck, Christopher A.
Independent Director
-
-

Daignault, Kenneth 
Independent Director
-
-

Emberton, Mark 
Medical Advisor of Prostate Cancer
-
-

Kamat, Ashish M.
Medical Advisor of Bladder Cancer
-
-

Matulewicz, Richard 
Medical Advisor of Bladder Cancer
-
-

Orczyk, Clement 
Medical Advisor of Prostate Cancer
-
-

Taneja, Samir 
Medical Advisor of Prostate Cancer
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Hutchens, Edward James
CEO, President & Director
(833) 246-2446
(508) 651-8955
jhutchens@imaginmedical.com
Vacha, John F.
CFO & Corporate Secretary
(617) 448-8379
-
jvacha@imaginmedical.com
Vergano, Michael G.
Director of Operations
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
